scholarly journals Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

2019 ◽  
Vol 17 (4) ◽  
pp. 367-402 ◽  
Author(s):  
Daniel G. Coit ◽  
John A. Thompson ◽  
Mark R. Albertini ◽  
Christopher Barker ◽  
William E. Carson ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Targeted Therapy ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Cutaneous Melanoma ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Distant Metastatic Disease ◽  
Nccn Guidelines ◽  
The Past

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.

Arteriovenous fistula cannulation in hemodialysis: A vascular access clinical practice guidelines narrative review

2021 ◽  
pp. 112972982110069
Author(s):  
Rui Pinto ◽  
Clemente Sousa ◽  
Anabela Salgueiro ◽  
Isabel Fernandes
Keyword(s):  
Clinical Practice ◽  
Arteriovenous Fistula ◽  
Vascular Access ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Good Evidence ◽  
Preparation Technique ◽  
Patient Centered ◽  
The Past ◽  
Centered Care

The cannulation of an arteriovenous fistula (AVF) by the hemodialysis (HD) nurse is challenging. Despite it being the focus of extensive research, it is still one of the majors causes of damage making it prone to failure. A considerable number of Clinical Practice Guidelines (CPGs) for the management of vascular access (VA) have been published worldwide over the past two decades. This review aimed to assess all information available in the selected CPG regarding AVF cannulation for HD providing a comprehensive analysis in order to interpret possible future cannulation approaches. A total of seven CPGs were described in a coding table separated in seven subthemes: Initiation of cannulation, preparation, technique, needle selection, surveillance, pain, and education. Our analysis outlines current CPGs for HD VA cannulation with lack of good evidence support for the majority of the recommendations, showing that, there is an urgent need for international collaboration and coordination to ensure relevant and high-quality evidence. Future CPGs must consider recommendations with better grading of evidence aiming patient-centered care and nurse decision models that can potentially represent better AVF cannulation outcomes.

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

2021 ◽  
Vol 19 (3) ◽  
pp. 329-359
Author(s):  
Al B. Benson ◽  
Alan P. Venook ◽  
Mahmoud M. Al-Hawary ◽  
Mustafa A. Arain ◽  
Yi-Jen Chen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Systemic Therapy ◽  
Checkpoint Inhibitors ◽  
Therapy Options ◽  
Nccn Guidelines ◽  
Positive Treatment ◽  
Biomarker Testing

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation–positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org. Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.

Level of Scientific Evidence Underlying Recommendations from the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 32-32
Author(s):  
Aakash Desai ◽  
Harry E Fuentes ◽  
Sri Harsha Tella ◽  
Caleb J Scheckel ◽  
Thejaswi Poonacha ◽  
...  
Keyword(s):  
Clinical Practice ◽  
National Comprehensive Cancer Network ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Scientific Evidence ◽  
Hematologic Malignancies ◽  
Level Of Evidence ◽  
Nccn Guidelines ◽  
Therapeutic Recommendations ◽  
Cancer Network

Background: National Comprehensive Cancer Network (NCCN) guidelines are the most comprehensive and widely used standard for clinical care in malignant hematology by clinicians and payers in the US. The level of scientific evidence in NCCN guidelines for malignant hematological conditions has not been recently investigated. We describe the distribution of categories of evidence and consensus (EC) among the 10 most common hematologic malignancies with regard to recommendations for staging, initial and salvage therapy, and surveillance. Methods: NCCN uses a system of guideline development distinct from other major professional organizations. The NCCN definitions for EC are: category I, high level of evidence such as randomized controlled trials with uniform consensus; category IIA, lower level of evidence with uniform consensus; category IIB, lower level of evidence without a uniform consensus but with no major disagreement; and category III, any level of evidence but with major disagreement. We compared our results with previously published results from 2011 guidelines. Results: Total recommendations increased by 16.6% from 1160 (2011) to 1353 (2020). Of the 1353 recommendations, Category 1, 2A, 2B and 3 EC were 5%, 91%, 4%, 1% while in 2011 they were 3%, 93%, 4% and 0% respectively. Recommendations with category 1 EC were found in all guidelines, except for Burkitt's Lymphoma. 6.3% of therapeutic recommendations were category 1 EC with the majority (56.4%) pertaining to initial therapy. Guidelines with highest proportions of therapeutic recommendations with category 1 EC were Multiple Myeloma (12.4%), CLL/SLL (6.9%) and AML (5.6%). Between 2011 and 2020, the proportion of category I recommendations increased significantly only in Follicular lymphoma and CLL/SLL. No category 1 EC recommendations existed in staging or surveillance. Conclusion: Recommendations issued in the 2020 NCCN guidelines are largely developed from lower levels of evidence but with uniform expert opinion. Despite the major advances in hematology in the past decade, this is largely unchanged. Our study underscores the urgent need and available opportunities to expand the current evidence base in malignant hematological disorders which forms the platform for clinical practice guidelines. Figure Disclosures No relevant conflicts of interest to declare.

scholarly journals Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2012 ◽  
Vol 23 ◽  
pp. vii86-vii91 ◽  
Author(s):  
R. Dummer ◽  
A. Hauschild ◽  
M. Guggenheim ◽  
U. Keilholz ◽  
G. Pentheroudakis
Keyword(s):  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Cutaneous Melanoma

Rectal Cancer Clinical Practice Guidelines in Oncology

2005 ◽  
Vol 3 (4) ◽  
pp. 492 ◽  
Keyword(s):  
Rectal Cancer ◽  
Colon Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Multidisciplinary Approach ◽  
The Past ◽  
Recent Version ◽  
The U.S ◽  
Cancer Panel

In 2005, an estimated 40,340 new cases of rectal cancer will occur in the U.S., and experts estimate that during the same year, 56,290 people will die of rectal and colon cancer. As with colon cancer, however, mortality from rectal cancer has also decreased over the past 30 years. The NCCN Rectal Cancer Panel believes a multidisciplinary approach is necessary for effectively managing rectal cancer, an approach detailed here. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Colon Cancer Clinical Practice Guidelines in Oncology

2003 ◽  
Vol 1 (1) ◽  
pp. 40 ◽  
Keyword(s):  
Colon Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
The United States ◽  
Treatment Modalities ◽  
Comprehensive Management ◽  
The Past ◽  
Management Algorithm ◽  
Recent Version

Colorectal cancer is the third most frequently diagnosed cancer in men and women in the United States, and in 2002, an estimated 107,300 new cases of colon cancer will have occurred. Despite these statistics, mortality from colon cancer has decreased over the past 30 years, possibly because of earlier diagnosis through screening and better treatment modalities. The NCCN clinical practice guidelines for managing colon cancer discuss these advances and provide a comprehensive management algorithm. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2019 ◽  
Vol 30 (12) ◽  
pp. 1884-1901 ◽  
Author(s):  
O. Michielin ◽  
A.C.J. van Akkooi ◽  
P.A. Ascierto ◽  
R. Dummer ◽  
U. Keilholz
Keyword(s):  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Cutaneous Melanoma

scholarly journals Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2015 ◽  
Vol 26 ◽  
pp. v126-v132 ◽  
Author(s):  
R. Dummer ◽  
A. Hauschild ◽  
N. Lindenblatt ◽  
G. Pentheroudakis ◽  
U. Keilholz
Keyword(s):  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Cutaneous Melanoma
Sign in / Sign up

Export Citation Format

Share Document